Plain-English translation of NCT07342491 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing whether a medication called can help reduce the hidden HIV that remains in your body even when your viral load is undetectable. People with well-controlled HIV on standard treatment often still have dormant virus hiding in their cells—this is called the HIV reservoir. The study wants to see if this medication can lower that reservoir and whether it is safe to take.
Even when HIV treatment works perfectly and your viral load becomes undetectable, the virus can hide in certain cells in your body. If you ever stop taking your medications, the hidden virus can wake up and cause disease again. Researchers are looking for new ways to reduce or eliminate this hidden reservoir so that people with HIV may eventually have more treatment options.
You likely qualify if…
You likely don't qualify if…
You will visit the clinic regularly over 36 weeks total. For the first 12 weeks, you'll take either the study medication or a placebo (a pill with no active drug) by mouth once daily—neither you nor the researchers will know which one you're taking. During and after the 12-week treatment period, you'll have blood tests and health check-ups to monitor your safety and how the medication affects the hidden HIV in your body. You'll also have follow-up visits and phone calls for 24 weeks after the treatment ends.
AI-generated summary from trial data · Aug 12, 2026 · Not medical advice
United States